Read by QxMD icon Read


Toshiyasu Ojima, Masaki Nakamura, Mikihito Nakamori, Masahiro Katsuda, Keiji Hayata, Shimpei Maruoka, Toshio Shimokawa, Hiroki Yamaue
Our previous trial with a docetaxel, cisplatin, and 5-fluorouracil (DCF) regimen showed high response rates in metastatic squamous cell carcinoma of the esophagus (SCCE). The observed increased toxicity of the DCF regimen, however, was clinically harmful. S-1, an oral anticancer drug, has been approved as a combination therapy for SCCE, and alternate-day regimen with S-1 has shown lower levels of toxicity. This prospective single-center phase I/II trial examines the efficacy and toxicity of a combination of docetaxel, cisplatin, and an alternate-day regimen of S-1 (modified DCS) for patients with metastatic SCCE...
May 16, 2018: Oncology
Teiji Kuzuya, Masatoshi Ishigami, Yoji Ishizu, Takashi Honda, Kazuhiko Hayashi, Tetsuya Ishikawa, Isao Nakano, Yoshiki Hirooka, Hidemi Goto
OBJECTIVES: The aim of this study was to investigate the prognostic factors associated with postprogression survival (PPS) in advanced hepatocellular carcinoma (HCC) patients treated with sorafenib, who were not eligible for second-line treatment with regorafenib. METHODS: A total of 103 patients with radiological confirmation of progressive disease (PD) were enrolled. RESULTS: The median PPS (n = 67) was 6.1 months. Significant and independent prognostic factors at initial radiological PD associated with good PPS were an Eastern Cooperative Oncology Group Performance Status (ECOG-PS) score of 0, the absence of macrovascular invasion (MVI), and time to progression (TTP) ≥4 months...
May 3, 2018: Oncology
Melanie B Thomas, Elizabeth Garrett-Mayer, Munazza Anis, Kate Anderton, Tricia Bentz, Andie Edwards, Alan Brisendine, Geoffrey Weiss, Abby B Siegel, Johanna Bendell, Ari Baron, Vinay Duddalwar, Anthony El-Khoueiry
OBJECTIVES: To investigate the clinical efficacy and tolerability of the combination of bevacizumab (B) and erlotinib (E) compared to sorafenib (S) as first-line treatment for patients with advanced hepatocellular carcinoma (HCC). METHODS: A total of 90 patients with advanced HCC, Child-Pugh class A-B7 cirrhosis, and no prior systemic therapy were randomly assigned (1: 1) to receive either 10 mg/kg B intravenously every 14 days and 150 mg E orally daily (n = 47) (B+E) or 400 mg S orally twice daily (n = 43)...
May 2, 2018: Oncology
Elena Elimova, Xuemei Wang, Wei Qiao, Kazuki Sudo, Roopma Wadhwa, Hironori Shiozaki, Yusuke Shimodaira, Venkatram Planjery, Nikolaos Charalampakis, Jeffrey H Lee, Brian R Weston, Manoop S Bhutani, Ritsuko Komaki, David C Rice, Stephen G Swisher, Mariela A Blum, Jane E Rogers, Heath D Skinner, Dipen M Maru, Wayne L Hofstetter, Jaffer A Ajani
OBJECTIVE: The goal of surveillance after therapy of localized esophageal cancer (LEC) is to identify actionable relapses amenable to salvage; however, the current surveillance algorithms are not optimized. We report on a large cohort of LEC patients with actionable locoregional relapses (LRRs). METHODS: Between 2000 and 2013, 127 (denominator = 752) patients with actionable LRR were identified. Histologic/cytologic confirmation was the gold standard. All surveillance tools (imaging, endoscopy, fine needle aspiration) were assessed...
April 27, 2018: Oncology
Noriko Nishinarita, Satoshi Igawa, Masashi Kasajima, Seiichiro Kusuhara, Shinya Harada, Yuriko Okuma, Keisuke Sugita, Takahiro Ozawa, Tomoya Fukui, Hisashi Mitsufuji, Masanori Yokoba, Masato Katagiri, Masaru Kubota, Jiichiro Sasaki, Katsuhiko Naoki
BACKGROUND: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKIs) therapy has been recognized as the standard treatment for patients with non-small cell lung cancer (NSCLC) harboring EGFR mutations. However, resistance to EGFR-TKIs has been observed in certain subpopulations of these patients. We aimed to evaluate the impact of smoking history on the efficacy of EGFR-TKIs. METHODS: The records of patients (n = 248) with NSCLC harboring activating EGFR mutations who were treated with gefitinib or erlotinib at our institution between March 2010 and June 2016 were retrospectively reviewed, and the treatment outcomes were evaluated...
April 26, 2018: Oncology
Mohamed Amine Elghali, Amine Gouader, Rym Bouriga, Mohamed Mahjoub, Mohamed Salah Jarrar, Sonia Ziadi, Moncef Mokni, Fahmi Hamila, Rached Ltaeif
INTRODUCTION: In developed countries, authors have reported variations over time in the seat and histological type of gastric adenocarcinomas, which were explained by Helicobacter pylori infection (HPI) incidence changes. In North-African countries and the Arabic world, epidemiological changes in gastric adenocarcinomas are still unknown. Our study aims to explore and to describe those changes in central Tunisia. MATERIALS AND METHODS: This is a retrospective observational and descriptive study including 876 cases based on the National Central Tunisian Register of Cancers over a period of 21 years...
April 25, 2018: Oncology
Junghoon Shin, Kyu Sang Lee, Kyung Ah Yoh, Hyun Jin Cho, Moon Ki Choi, Se Hyun Kim, Yu Jung Kim, Jin-Haeng Chung, Sukki Cho, Kwhanmien Kim, Sanghoon Jheon, Ho Il Yoon, Jae Ho Lee, Choon-Taek Lee, Jong Seok Lee
OBJECTIVE: Multimodal treatments that include preoperative platinum-based chemotherapy are fundamental to the treatment of advanced non-small cell lung cancer (NSCLC). This study aimed to investigate the predictive value of DNA repair protein expression in surgically resected NSCLCs in terms of prognosis and responses to platinum-containing chemotherapy. METHODS: This retrospective study included 136 patients with NSCLC who were treated with preoperative platinum-based chemotherapy, followed by curative lung resection...
April 25, 2018: Oncology
Mehran Yusuf, Beatrice Ugiliweneza, Mark Amsbaugh, Maxwell Boakye, Brian Williams, Megan Nelson, Eyas M Hattab, Shiao Woo, Eric Burton
OBJECTIVE: In this phase II study, we investigate clinical outcomes and tolerability of hypofractionated radiotherapy (HRT) combined with temozolomide (TMZ) to treat elderly patients with glioblastoma (GBM). METHODS: Patients 70 years of age or older with newly diagnosed GBM received HRT to a dose of 34 Gy given in ten fractions over 2 weeks, delivered with concurrent and adjuvant TMZ. RESULTS: In this interim analysis, ten patients were enrolled on trial from 12/1/2015 to 4/5/2017...
April 25, 2018: Oncology
Aaron M Allen, Tzippy Shochat, Dov Flex, Mordechai R Kramer, Alona Zer, Nir Peled, Elizabeta Dudnik, Eyal Fenig, Milton Saute
BACKGROUND: Trimodality therapy (chemoradiation followed by surgery) provides a benefit in progression-free survival but not overall survival. We sought to determine if a high dose of radiation could be delivered safely and provide a clinical benefit. METHODS: Consecutive patients with stage IIIA or IIIB non-small-cell lung cancer (NSCLC) treated with concurrent chemoradiotherapy followed by surgery were reviewed with IRB approval. RESULTS: A total of 48 patients were treated from November 2007 to May 2014...
April 20, 2018: Oncology
Miriam Schlegel, Martina Zeumer, Peter Michael Prodinger, Klaus Woertler, Marc Steinborn, Rüdiger von Eisenhart-Rothe, Stefan Burdach, Hans Rechl, Irene von Luettichau
BACKGROUND: The purpose of this study was to investigate whether pathological fractures (PF) influence the prognosis of patients with osteosarcoma (OS) or Ewing tumor (ET) regarding 5-year survival, occurrence of metastases, and local recurrence. METHODS: We retrospectively analyzed 205 patients with metastatic and nonmetastatic OS or ET. Survival analysis was performed for all patients and differentiated for patients with OS (n = 127) and ET (n = 78) as well as for adults (n = 101) and children (n = 104)...
April 13, 2018: Oncology
Hangzhan Ma, Xiaoyang Li, Jinglu Wang, Francis J Hornicek, Cassandra C Garbutt, Xu Chang, Zhenfeng Duan
PURPOSE: Recent studies highlight the role of autophagy in cancer tumorigenesis, recurrence, metastasis, and chemoresistance. p62 is an adapter protein that is crucial for the autophagy pathway. In this study, we will describe the expression of p62 and its correlation with clinic prognosis in osteosarcoma. METHODS: Western blot was used to test the expression of p62 in osteosarcoma cell lines (U2OS, KHOS, MG63, Saos-2, U2OSR2, KHOSR2, and 143B). A tissue microarray (TMA) was analyzed by immunohistochemistry to determine the expression levels of p62 in osteosarcoma patients and evaluate any correlation between p62 and clinical characteristics in osteosarcoma patients...
April 4, 2018: Oncology
Masafumi Yoshimoto, Aoi Tokuda, Kunihiko Nishiwaki, Kazuo Sengoku, Yuji Yaginuma
OBJECTIVE: The protein interacting with carboxyl terminus-1 (PICT-1) gene has been implicated as a tumor suppressor gene, and its alterations have been reported in several cancers. This study investigated the association of PICT-1 alterations with endometrial carcinogenesis. METHODS: We analyzed the entire coding region of the PICT-1 gene using polymerase chain reaction-single-strand conformation polymorphism and DNA sequencing to examine PICT-1 mutations in endometrial cancer...
April 4, 2018: Oncology
Takahiro Ebata, Tatsunori Shimoi, Seiko Bun, Mototaka Miyake, Akihiko Yoshida, Akihiko Shimomura, Emi Noguchi, Kan Yonemori, Chikako Shimizu, Yasuhiro Fujiwara, Yoshitaka Narita, Kenji Tamura
OBJECTIVE: To investigate the efficacy and safety of pazopanib for recurrent or metastatic solitary fibrous tumor (SFT) in first- and second-line settings. METHODS: Patients histologically diagnosed with SFT at our hospital who received pazopanib monotherapy for inoperable disease between January 2013 and November 2016 were eligible. We retrospectively investigated treatment outcomes according to the treatment lines and assessed adverse events. RESULTS: Nine patients were eligible...
April 3, 2018: Oncology
Jorge Aparicio, Alfonso Sánchez-Muñoz, Josep Gumà, Montserrat Domenech, José A Meana, José García-Sánchez, Romà Bastús, Regina Gironés, Enrique González-Billalabeitia, Naiara Sagastibelza, Sebastián Ochenduszko, Alfredo Sánchez, Josefa Terrasa, Josep R Germà-Lluch, Xavier García Del Muro
OBJECTIVE: The aim of this study was to assess a risk-adapted strategy for stage I seminoma guided by the presence of rete testis invasion. METHODS: Between January 2013 and December 2015, a total of 135 consecutive patients with stage I seminoma from 18 Spanish tertiary hospitals were included in a prospective multicenter study. Median patient age was 38 years (range 22-60). Preoperative beta-human chorionic gonadotropin was elevated in 9.6% of patients. Rete testis invasion was present in 47...
March 26, 2018: Oncology
Nathália Kersting, Bárbara Kunzler Souza, Igor Araujo Vieira, Rafael Pereira Dos Santos, Danielly Brufatto Olguins, Lauro José Gregianin, André Tesainer Brunetto, Algemir Lunardi Brunetto, Rafael Roesler, Caroline Brunetto de Farias, Gilberto Schwartsmann
OBJECTIVE: Ewing sarcoma (ES) is a type of childhood cancer probably arising from stem mesenchymal or neural crest cells. The epidermal growth factor receptor (EGFR) acts as a driver oncogene in many types of solid tumors. However, its involvement in ES remains poorly understood. METHODS: Human SK-ES-1 and RD-ES ES cells were treated with EGF, the EGFR inhibitor tyrphostin (AG1478), or phosphoinositide 3-kinase (PI3K) or extracellular-regulated kinase (ERK)/mitogen-activated kinase (MAPK) inhibitors...
March 14, 2018: Oncology
Li Rebekah Feng, Alexandra Espina, Leorey N Saligan
PURPOSE: Cancer-related fatigue is a common complaint during cancer treatment and is often associated with cognitive impairment. This study examined cognitive deficits that were associated with fatigue symptoms during external-beam radiation therapy (EBRT) in men with localized prostate cancer. METHODS: A total of 36 participants were enrolled and followed up at baseline, 24 h, 7 days, 14 days after EBRT initiation, at midpoint, and at completion of EBRT. Fatigue was measured by self-report using the Functional Assessment of Cancer Therapy - Fatigue (FACT-F), and cognitive impairment by the Computer Assessment of Mild Cognitive Impairment (CAMCI®)...
March 7, 2018: Oncology
Bruno Vincenzi, Giuseppe Badalamenti, Grazia Armento, Marianna Silletta, Mariella Spalato Ceruso, Giovanna Catania, Andrea Napolitano, Giuseppa Maltese, Sergio Valeri, Lorena Incorvaia, Daniele Santini, Giuseppe Tonini
OBJECTIVES: Low body mass index (BMI) and/or low lean body mass have been shown to be risk factors for chemotherapy-related toxicities in a number of different cancers. However, no data are available regarding the role of BMI as a risk factor for developing toxicities related to the novel anticancer agent, trabectedin, in patients with soft-tissue sarcoma (STS). We evaluated the role of BMI as a risk factor for trabectedin-related toxicity in patients with STS. METHODS: Data from 51 patients with metastatic/advanced STS treated with trabectedin after progression on ≥1 anthracycline ± ifosfamide regimen were retrospectively reviewed...
March 6, 2018: Oncology
Cheol-Kyu Park, In-Jae Oh, Yoo-Duk Choi, Tae-Won Jang, Jeong-Eun Lee, Jeong-Seon Ryu, Shin-Yup Lee, Young-Chul Kim
OBJECTIVES: We aimed to evaluate the prevalence and predictive role of c-MET expression and EGFR mutation in the efficacy of erlotinib in non-small-cell lung cancer (NSCLC). METHODS: We prospectively recruited 196 patients with stage IV or recurrent NSCLC treated with erlotinib after failure of first-line chemotherapy. Immunohistochemistry was used to evaluate c-MET overexpression, silver in situ hybridization (SISH) to assess gene copy number, and real-time polymerase chain reaction to detect EGFR mutations, respectively, in tumor tissue...
March 2, 2018: Oncology
Kevin Zarrabi, Shenhong Wu
BACKGROUND: Nivolumab is approved for the treatment of many cancers. This meta-analysis was conducted to determine the risk of hepatotoxicity with nivolumab therapy. METHODS: An analysis from all phase I-III clinical trials up to December 2016 examining nivolumab was conducted. Data on elevations in aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were extracted from the safety profiles of each trial. Incidence and relative risk (RR) were calculated using random- or fixed-effects models with 95% confidence intervals (CIs)...
2018: Oncology
Rie Kanaoka, Hisae Iinuma, Hitoshi Dejima, Takashi Sakai, Hirofumi Uehara, Noriyuki Matsutani, Masafumi Kawamura
OBJECTIVES: The aim of this study was to clarify the usefulness of plasma exosomal microRNA-451a (miR-451a) as a novel biomarker for the early prediction of recurrence and prognosis in non-small cell lung cancer (NSCLC) patients after curative resection. METHODS: Before surgery, plasma samples were collected and exosomal microRNA (miRNA) levels were evaluated. We first profiled specific exosomal miRNAs related to recurrence in 6 NSCLC patients with stage IA cancer by miRNA microarray...
2018: Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"